Apollo Hospitals Stock Hits Record After Company Sells Stake In Subsidiary Apollo HealthCo To Rasmeli

Rasmeli has acquired a 16.9% stake in Apollo HealthCo, effectively reducing Apollo Hospitals' ownership from 94.91% to 78.87%.

Apollo's stake in its unit Apollo HealthCo has been diluted from 94.91% to 78.87%.

(Source: Apollo Hospitals Enterprise website)

Shares of Apollo Hospitals Enterprise Ltd. hit a life high on Monday after Rasmeli Ltd., an affiliate of global private equity firm Advent International, bought 16.9% stake in the company's subsidiary Apollo HealthCo Ltd. for over Rs 2,475 crore.

This transaction has effectively reduced Apollo Hospitals' ownership from 94.91% to 78.87%, according to an exchange filing on Friday.

Additionally, the plan includes Apollo HealthCo acquiring an 11.2% stake in Keimed, a key distributor of pharmaceutical products, for Rs 625 crore. Apollo Hospitals' promoter, Shobana Kamineni, will be selling her personal shares in Keimed to Apollo HealthCo, according to the filing. Furthermore, Apollo HealthCo has given Keimed Rs 99.9 crore in primary investments to fuel its expansion plans.

The third component of this proposed transaction is Keimed's upcoming merger with Apollo HealthCo. This merger would create a more streamlined structure under the subsidiary, further strengthening Apollo's digital health ecosystem. These transactions involve the issuance of preference shares in multiple tranches, as per the filing.

Also Read: Apollo Hospitals To Focus On Asset Utilisation, Cost Reduction To Boost FY25 Margins

Shares of the company rose as much as 1.15% to Rs 7,316.95 apiece, the highest level since listing. The stock pared gains to trade 0.48 % higher at Rs 7,268.70 apiece as of 10:15 a.m. This compares to a 0.76 decline in the NSE Nifty 50 Index.

The stock has risen 26.49% on a year-to-date basis. Total traded volume so far in the day stood at 0.25 times its 30-day average. The relative strength index was at 73.62, indicating that the stock may be overbought.

Out of 28 analysts tracking the company, 23 maintain a 'buy' rating, three recommend a 'hold,' and two suggest a 'sell,' according to Bloomberg data. The average 12-month consensus price target implies an downside of 0.8%.

Also Read: Stock Market Today: Nifty, Sensex Record Worst Day In Nearly Two Months As RIL, ICICI Bank Weigh

Watch LIVE TV , Get Stock Market Updates, Top Business , IPO and Latest News on NDTV Profit.
WRITTEN BY
Divya Prata
Divya Prata is a desk writer at NDTV Profit, covering business and market n... more
GET REGULAR UPDATES